PT - JOURNAL ARTICLE AU - Sarah White AU - Elizabeth Laurenzana AU - Howard Hendrickson AU - W. Brooks Gentry AU - S. Michael Owens TI - Gestation Time-Dependent Pharmacokinetics of Intravenous (+)-Methamphetamine in Rats AID - 10.1124/dmd.111.039446 DP - 2011 Sep 01 TA - Drug Metabolism and Disposition PG - 1718--1726 VI - 39 IP - 9 4099 - http://dmd.aspetjournals.org/content/39/9/1718.short 4100 - http://dmd.aspetjournals.org/content/39/9/1718.full SO - Drug Metab Dispos2011 Sep 01; 39 AB - We tested the hypothesis that differences in (+)-methamphetamine (METH) disposition during late rat pregnancy could lead to increased vulnerability to acute METH effects. The disposition of a single 1 mg/kg i.v. METH dose was studied during early (gestation day 7, GD7) and late (GD21) gestation. Results showed gestation time-dependent pharmacokinetics, characterized by a significantly higher area under the METH serum concentration versus time curve and a lower clearance on GD21 (p < 0.05; total, renal, and nonrenal clearance). The terminal elimination half-life (t1/2λz) of METH and (+)-amphetamine (AMP; a pharmacologically active metabolite of METH) were not different on GD7, but by GD21, AMP t1/2λz was 37% longer than METH t1/2λz (p < 0.05). To identify the mechanism for AMP metabolite changes, intravenous AMP pharmacokinetics on GD21 were compared with AMP metabolite pharmacokinetics after intravenous METH. The intravenous AMP t1/2λz was significantly shorter than metabolite AMP t1/2λz (p < 0.05), which suggested AMP metabolite formation (not elimination) was the rate-limiting process. To understand the medical consequence of METH use during late-stage pregnancy, timed-pregnant rats received an intravenous dose of saline or METH (1, 3, or 5.6 mg/kg) on GD21, 0 to 2 days antepartum. Although one rat died and another had stillbirths at term after the 5.6-mg/kg dose, the pharmacokinetic values for all of the other animals were not significantly different. In conclusion, late-gestational clearance reductions lengthen METH exposure time, possibly increasing susceptibility to adverse effects, including death.